Ranger Investment Management L.P. Makes New $21.05 Million Investment in LeMaitre Vascular, Inc. $LMAT

Ranger Investment Management L.P. acquired a new position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the second quarter, Holdings Channel.com reports. The institutional investor acquired 219,307 shares of the medical instruments supplier’s stock, valued at approximately $21,045,000.

A number of other institutional investors have also made changes to their positions in LMAT. BlackRock Inc. bought a new stake in LeMaitre Vascular during the second quarter worth approximately $314,075,000. Vanguard Group Inc. raised its position in shares of LeMaitre Vascular by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 1,622,033 shares of the medical instruments supplier’s stock valued at $131,547,000 after purchasing an additional 21,946 shares during the period. Conestoga Capital Advisors LLC lifted its stake in shares of LeMaitre Vascular by 3.6% in the first quarter. Conestoga Capital Advisors LLC now owns 1,476,813 shares of the medical instruments supplier’s stock worth $161,224,000 after buying an additional 51,825 shares during the last quarter. First Trust Advisors LP boosted its holdings in shares of LeMaitre Vascular by 6.2% during the 1st quarter. First Trust Advisors LP now owns 998,071 shares of the medical instruments supplier’s stock worth $108,959,000 after buying an additional 57,931 shares during the period. Finally, State Street Corp boosted its holdings in shares of LeMaitre Vascular by 0.8% during the 4th quarter. State Street Corp now owns 806,993 shares of the medical instruments supplier’s stock worth $65,447,000 after buying an additional 6,130 shares during the period. 84.64% of the stock is owned by institutional investors.

LeMaitre Vascular Stock Performance

Shares of LMAT opened at $81.86 on Monday. LeMaitre Vascular, Inc. has a 12-month low of $78.65 and a 12-month high of $118.01. The company has a quick ratio of 13.96, a current ratio of 16.31 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $1.87 billion, a price-to-earnings ratio of 28.72, a P/E/G ratio of 2.36 and a beta of 0.53. The stock’s 50-day moving average price is $94.38 and its 200 day moving average price is $99.67.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Tuesday, August 4th. The medical instruments supplier reported $0.74 EPS for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.07). LeMaitre Vascular had a return on equity of 15.63% and a net margin of 25.02%.The firm had revenue of $70.38 million during the quarter, compared to the consensus estimate of $71.47 million. During the same quarter in the prior year, the business posted $0.60 EPS. LeMaitre Vascular’s revenue was up 9.6% compared to the same quarter last year. As a group, research analysts predict that LeMaitre Vascular, Inc. will post 2.89 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 3rd. Shareholders of record on Thursday, August 20th will be paid a dividend of $0.25 per share. The ex-dividend date is Thursday, August 20th. This represents a $1.00 dividend on an annualized basis and a yield of 1.2%. LeMaitre Vascular’s payout ratio is currently 35.09%.

Analyst Ratings Changes

A number of research analysts recently issued reports on LMAT shares. Citigroup reiterated a “market outperform” rating on shares of LeMaitre Vascular in a research note on Tuesday, July 21st. Weiss Ratings cut shares of LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, August 14th. Barrington Research downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 5th. Wells Fargo & Company dropped their price objective on LeMaitre Vascular from $104.00 to $94.00 and set an “equal weight” rating on the stock in a research note on Wednesday, August 5th. Finally, Wall Street Zen cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Three research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, LeMaitre Vascular presently has an average rating of “Hold” and an average target price of $110.60.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.